AHCO:NSD-Adapthealth Corp (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 21.40

Change

-0.04 (-0.19)%

Market Cap

USD 2.93B

Volume

0.28M

Avg Analyst Target

USD 27.43 (+28.17%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AHCO Stock Forecast & Price:
Based on the Adapthealth Corp stock forecasts from 5 analysts, the average analyst target price for Adapthealth Corp is USD 27.43 over the next 12 months. Adapthealth Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adapthealth Corp is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Adapthealth Corp’s stock price was USD 21.40. Adapthealth Corp’s stock price has changed by -0.47% over the past week, -6.63% over the past month and +6.26% over the last year.

About Adapthealth Corp (AHCO:NSD)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to indivi ...Read More

Company Website : https://adapthealth.com

Address : 220 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Employees : 10,700

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.76

52 Week High : 27.48

Short Ratio : 10.94

52 Week Low : 11.40

Shorted Shares : 10,165,562

200 Day Moving Average : 18.69

Shorted Shares Previous Month : 10,440,270

50 Day Moving Average : 21.11

Shares Held By Insiders : 24.84%

Short Percentage : 10.31%

Shares Held by Institutions : 75.47%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

-2.18 (-1.94%)

 USD43.26B 254.55 99.15
PODD Insulet Corporation

-3.75 (-1.28%)

 USD20.30B 1,217.96 173.95
ABMD ABIOMED Inc

+0.10 (+0.03%)

 USD17.05B 64.85 57.56
ALGN Align Technology Inc

+2.05 (+1.08%)

 USD15.21B 30.32 18.96
LVGO Livongo Health, Inc

N/A

 USD14.20B N/A N/A
BRKR Bruker Corporation

-1.11 (-1.68%)

 USD10.12B 37.80 20.17
SWAV Shockwave Medical Inc

-7.53 (-2.93%)

 USD9.55B 102.83 96.76
IART Integra LifeSciences Holdings

+0.59 (+1.11%)

 USD4.51B 26.34 15.45
NARI Inari Medical Inc

-1.52 (-2.06%)

 USD4.02B N/A -301.86
WMGI Wright Medical Group N.V

N/A

 USD3.90B N/A 50.67

ETFs Containing AHCO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.51% 81% B- 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.51% 81% B- 60% D-
Trailing 12 Months  
Capital Gain 9.02% 87% B+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.02% 87% B+ 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.03% 66% D 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.03% 66% D 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 72.98% 31% F 16% F
Risk Adjusted Return 26.08% 71% C- 66% D
Market Capitalization 2.93B 91% A- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.43 48% F 29% F
Price/Book Ratio 1.35 69% D+ 56% F
Price / Cash Flow Ratio 10.62 22% F 22% F
EV/EBITDA 9.17 17% F 25% F
Management Effectiveness  
Return on Equity 4.73% 87% B+ 64% D
Return on Invested Capital 7.05% 87% B+ 71% C-
Return on Assets 3.09% 88% B+ 78% C+
Debt to Equity Ratio 105.90% 24% F 20% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 10.94 17% F 9% F
Short Percent 10.31% 11% F 15% F
Beta 0.76 80% B- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.